The creation of CARB-X was prioritized in the 2015 US National Action Plan on Combating Antibiotic-Resistant Bacteria (CARB), which called for a biopharmaceutical accelerator to spur pre-clinical product development.

CARB-X turns 90 (days, that is)!

October 26, 2016

By Tyler Merkeley, BARDA

It has been 90 days since we launched the world’s largest global antibacterial public-private partnership to combat antibiotic resistant bacteria. Arguably, we have already started changing the way pre-clinical antibacterial product development is identified, funded, and soon, how it will be managed.


The Founders of CARB-X Share Their Vision

Key Partners


CARB-X launched on July 28, 2016. Please go to the Application and Events pages for updates on funding calls and opportunities to meet with the CARB-X team.

  • In the first year, $50 million will be committed to research, including $30 million in BARDA funds.

  • CARB-X Cycles 1 & 2 are now closed.

Contact Information

765 Commonwealth Ave, Suite 1201
Boston, MA 02215

Register your email below to receive announcements about CARB-X:

Thanks for registering!